{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:13:35Z","timestamp":1794892415783,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.esmoop.2026.106070","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T22:14:01Z","timestamp":1770243241000},"page":"106070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC"],"prefix":"10.1016","volume":"11","author":[{"given":"N.","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-3646","authenticated-orcid":false,"given":"J.","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7018-9556","authenticated-orcid":false,"given":"P.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-5524","authenticated-orcid":false,"given":"C.","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3151-6427","authenticated-orcid":false,"given":"D.C.","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-6125","authenticated-orcid":false,"given":"P.","family":"Garrido Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gregorc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-3628","authenticated-orcid":false,"given":"V.D.","family":"Haakensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0665-2160","authenticated-orcid":false,"given":"T.J.N.","family":"Hiltermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-7397","authenticated-orcid":false,"given":"S.","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mornex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moskovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-7143","authenticated-orcid":false,"given":"S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3059-5730","authenticated-orcid":false,"given":"B.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-7744","authenticated-orcid":false,"given":"Y.","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Shcherbakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Diaz Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7159-7869","authenticated-orcid":false,"given":"A.R.","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 23","key":"10.1016\/j.esmoop.2026.106070_bib1","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1002\/cncr.29045","article-title":"Analysis of stage and clinical\/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system","volume":"120","author":"Chen","year":"2014","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106070_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/thoraxjnl-2012-202297","article-title":"Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007","volume":"68","author":"Walters","year":"2013","journal-title":"Thorax"},{"issue":"20","key":"10.1016\/j.esmoop.2026.106070_bib4","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.esmoop.2026.106070_bib5","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106070_bib6","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of stage III non-small-cell lung cancer: ASCO Guideline","volume":"40","author":"Daly","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106070_bib7","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106070_bib8","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106070_bib9","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","article-title":"Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study","volume":"20","author":"Hui","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106070_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106070_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.106070_bib14","article-title":"A real-world, multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable stage III non-small cell lung cancer","volume":"11","author":"Bruni","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.106070_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2020.10.006","article-title":"Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP)","volume":"150","author":"Faehling","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.106070_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1506172","article-title":"Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec\u2019s University teaching hospitals","volume":"14","author":"Labrie","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106070_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.7542","article-title":"Durvalumab after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer","volume":"7","author":"Mooradian","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106070_bib18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10637-021-01091-9","article-title":"Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients","volume":"39","author":"Taugner","year":"2021","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106070_bib19","article-title":"Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: real-world data from an expanded access program in Brazil (LACOG 0120)","volume":"50","author":"Zukin","year":"2025","journal-title":"J Bras Pneumol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106070_bib20","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s12094-024-03404-9","article-title":"The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy","volume":"26","author":"Gomez Rueda","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2026.106070_bib21","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/1759-7714.14667","article-title":"Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer","volume":"13","author":"Huang","year":"2022","journal-title":"Thorac Cancer"},{"issue":"28","key":"10.1016\/j.esmoop.2026.106070_bib22","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2217\/fon-2023-0117","article-title":"Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting","volume":"19","author":"Waterhouse","year":"2023","journal-title":"Future Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2026.106070_bib23","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106070_bib24","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/jamaoncol.2019.2055","article-title":"Factors associated with age disparities among cancer clinical trial participants","volume":"5","author":"Ludmir","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106070_bib25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.21037\/tlcr.2018.09.15","article-title":"Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice","volume":"8","author":"Rashdan","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106070_bib26","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","volume":"31","author":"Paz-Ares","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106070_bib27","article-title":"Concurrent chemoradiotherapy in non-small cell lung cancer","author":"O\u2019Rourke","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.106070_bib28","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106070_bib29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/annonc\/mdn559","article-title":"Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study","volume":"20","author":"De Ruysscher","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106070_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2016.07.025","article-title":"Stage III non-small cell lung cancer in the elderly: patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice","volume":"121","author":"Driessen","year":"2016","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106070_bib31","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1186\/s12885-021-08577-y","article-title":"Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer","volume":"21","author":"Hung","year":"2021","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106070_bib32","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.clon.2017.07.012","article-title":"Treatment variation of sequential versus concurrent chemoradiotherapy in stage III non-small cell lung cancer patients in the Netherlands and Belgium","volume":"29","author":"Walraven","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106070_bib33","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.106070_bib34","article-title":"LBA6 PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)","volume":"35","author":"Wu","year":"2024","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:34:00Z","timestamp":1773988440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2059702926000128"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106070","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106070"}}